Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
March 08, 2025 09:00 ET
|
Alumis Inc.
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
February 28, 2025 09:08 ET
|
Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025 16:45 ET
|
Alumis Inc.
Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
Plaque Psoriasis Market Research 2024-2034: Environmental and Genetic Factors Boost Demand, Investments in Medical R&D Catalyze Innovations
January 23, 2025 04:44 ET
|
Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
Mindera Health™ Signs Network Provider Agreement with MultiPlan
December 16, 2024 08:00 ET
|
Mindera Health
Vista, CA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks....
Mindera Health™ Welcomes New Vice President of Sales
December 05, 2024 08:00 ET
|
Mindera Health
Vista, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a pioneer in precision medicine combining machine learning with Next-Generation Sequencing to create Dermal Intelligence™, announces the...
Plaque Psoriasis Research Report 2024: 7 Major Market and 61 Additional Country Market Analysis and Sales Forecasts 2020-2030
November 18, 2024 10:55 ET
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.The analyst estimates that sales...
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
November 13, 2024 16:05 ET
|
Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
Dermatology Collaboration and Licensing Agreements Analysis Report 2024: Detailed Review and Access to Contract Documents - Upfront, Milestone, Royalties, Company A-Z, Therapy and Technology
November 11, 2024 04:47 ET
|
Research and Markets
Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Understanding the United States Psoriasis Patient Experience to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
October 25, 2024 04:05 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. This...